At a glance
- Originator Egis Pharmaceuticals
- Class Anxiolytics; Isoquinolines; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Anxiety disorders
Most Recent Events
- 07 Jun 2001 No-Development-Reported for Anxiety disorders in Hungary (Unknown route)
- 22 Jul 1997 New profile
- 22 Jul 1997 Preclinical development for Anxiety disorders in Hungary (Unknown route)